Prostatype Genomics Liabilities
The The Liabilities of Prostatype Genomics (PROGEN.ST) as of Oct 13, 2026 is 24.33 M SEK. In the previous year, The Liabilities was 8.50 M SEK — a change of 186.24% (higher).
Get this data via API
Financial Data API
Liabilities
24.33 MSEK
YoY
186.24%
Last updated:
In 2025, Prostatype Genomics's total liabilities amounted to 24.33 M SEK, a 186.24% difference from the 8.50 M SEK total liabilities in the previous year.
The Prostatype Genomics Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Liabilities | YoY |
|---|---|---|
| 24.33 MSEK | +186.24% | |
| 8.50 MSEK | -65.37% | |
| 24.55 MSEK | +411.52% | |
| 4.80 MSEK | +11.68% | |
| 4.30 MSEK | -20.02% | |
| 5.37 MSEK | -40.49% | |
| 9.03 MSEK | -33.07% | |
| 13.49 MSEK | +181.80% | |
| 4.79 MSEK | -12.42% | |
| 5.47 MSEK | — |
Prostatype Genomics Stock analysis
Liabilities Details
Assessing Prostatype Genomics's Liabilities
Prostatype Genomics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Prostatype Genomics's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Prostatype Genomics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Prostatype Genomics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Prostatype Genomics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Prostatype Genomics stock
The Liabilities of Prostatype Genomics is 24.33 M SEK in 2025.
The Liabilities of Prostatype Genomics changed from 8.50 M SEK to 24.33 M SEK, representing a 186.24% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of The Liabilities Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.
The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Prostatype Genomics historically and in real time.
Balance Sheet — Prostatype Genomics
All Key Metrics — Prostatype Genomics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth